Novel Cell Therapy Platform for Cancer using Engineered cDC1 Dendritic Cells
— Published date: 5/30/2026
Value Proposition: CAR-engineered cDC1 cells (syngeneic or allogeneic) that stably express a proprietary, modular chimeric antigen receptor and demonstrate strong in vivo efficacy against solid tumors, including immunologically ‘cold’ tumors.
Technology Descr…
